Get the Stockscreener App
6.97
1.83%
-0.13
Immunic Inc stock is traded at $6.97, with a volume of 366.22K.
It is down -1.83% in the last 24 hours and down -31.13% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
See More
Previous Close:
$7.10
Open:
$7.1
24h Volume:
366.22K
Relative Volume:
0.89
Market Cap:
$95.10M
Revenue:
Net Income/Loss:
$-104.29M
P/E Ratio:
-1.1553
EPS:
-6.0329
Net Cash Flow:
$-81.45M
1W Performance:
-14.90%
1M Performance:
-31.13%
6M Performance:
-30.30%
1Y Performance:
-14.57%
1-Day Range:
$6.80
$7.92
1-Week Range:
$6.35
$8.444
52-Week Range:
$5.062
$17.43
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
6.97 | 95.10M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-17-26 | Initiated | Wedbush | Outperform |
| May-22-26 | Initiated | Wolfe Research | Outperform |
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-15-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Stocks fall sharply as Syndax trial fails and S... - Pluang
Seven new Immunic employees get stock options tied to 196,350 shares - Stock Titan
Form 4 Immunic Inc For: 28 September By Investing.com - Investing.com UK
Form 4 Immunic Inc For: 28 September By Investing.com - Investing.com Canada
Form 4 Immunic Inc For: 28 September By Investing.com - Investing.com India
Director at Immunic (IMUX) gets options at $10.12 a share - Stock Titan
New option grant tied to Immunic (IMUX) director - Stock Titan
Immunic announces resignation of director Duane Nash and board size reduction By Investing.com - Investing.com Australia
Immunic Director Dr. Duane Nash Resigns; Board Cut to Nine Members - minichart.com.sg
Form 8K Immunic Inc For: 11 September By Investing.com - Investing.com South Africa
Immunic announces resignation of director Duane Nash and board size reduction - Investing.com
Form 8K Immunic Inc For: 11 September By Investing.com - Investing.com Nigeria
Form 8K Immunic Inc For: 11 September By Investing.com - Investing.com Canada
Immunic announces resignation of director Duane Nash and board size reduction - Investing.com
Dr. Duane Nash resigns from Immunic board; board reduced to nine members - TradingView
Immunic director Duane Nash resigns, board shrinks to nine members - Bitget
H.C. Wainwright reiterates Immunic stock rating on MS drug progress By Investing.com - Investing.com Nigeria
Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 BaselSlideshow (NASDAQ:IMUX) 2026-09-10 - Seeking Alpha
IMUX Reiterated by Wedbush -- Price Target Maintained at $45 - GuruFocus
Why Is Immunic (NASDAQ:IMUX) Advancing Its MS Drug Program? - Kalkine Media
Stifel reiterates Immunic stock rating on MS drug potential By Investing.com - Investing.com Canada
Stifel reiterates Immunic stock rating on MS drug potential - investing.com
H.C. Wainwright reiterates Immunic stock rating on MS drug progress By Investing.com - Investing.com Canada
IMUX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $22 - GuruFocus
Immunic, Inc. R&D Day Transcript - GuruFocus
IMUX: Pivotal Phase 3 data for vidofludimus calcium in relapsing MS expected by end of 2026 - TradingView
Immunic (NASDAQ: IMUX) plans Sept. 9 relapsing MS R&D webinar - stocktitan.net
Immunic hosts RMS R&D Day webinar, presents vidofludimus calcium program and forward-looking plans - TradingView
Small cap wrap: Immunic, Midnight Sun Mining, Purepoint Uranium... - proactiveinvestors.com.au
Immunic to host virtual R&D day on relapsing MS ahead of Phase 3 trial results - Pluang
Immunic to host virtual relapsing MS R&D Day on September 9 - Yahoo Finance
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PR Newswire
EQS-News: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026boerse.de - boerse.de
Immunic to host virtual relapsing MS R&D Day on September 9 - Proactive financial news
Immunic names Chitrang Davé chief data and digital officer - thepharmaletter.com
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - Investing News Network
Immunic appoints Chitrang Davé as chief data and digital officer - Yahoo Finance
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - PR Newswire
Immunic appoints Chitrang Davé as chief data and digital officer - Proactive financial news
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating (NASDAQ:IMUX) - Seeking Alpha
Long term debt to total assets ratio of Immunic, Inc. – HAM:10V - TradingView
Discontinued operations of Immunic, Inc. – HAM:10V - TradingView
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com Australia
IMUX Initiates Coverage On Wedbush -- Rating Set to Outperform - GuruFocus
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com Nigeria
Wedbush initiates Immunic stock with Outperform rating - Investing.com
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com Canada
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com UK
Renaissance Technologies LLC Invests $1.02 Million in Immunic, Inc. $IMUX - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):